Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023
Funds Expected to Support the Recently Announced Accelerated Development of AL102 for the Treatment of Desmoid Tumors into Pivotal Phase 2/3 Study
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia June 2, 2021 at 7:0
The study aims to further validate the anti-fibrotic and anti-inflammatory activity of CM-101 while providing safety and PK data to support development of the subcutaneous formulation TEL-AVIV, Israel
- Under the terms of the research collaboration and exclusive option agreement, the companies will initiate a gene editing research program dedicated to the treatment of two early onset indications wi